Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Qiao G, Wang X, Zhou X, Morse MA, Wu J, Wang S, Song Y, Jiang N, Zhao Y, Zhou L, Zhao J, Di Y, Zhu L, Hobeika A, Ren J, Lyerly HK. Qiao G, et al. Among authors: jiang n. Int J Hyperthermia. 2019 Nov;36(sup1):74-82. doi: 10.1080/02656736.2019.1647350. Int J Hyperthermia. 2019. PMID: 31795830 Free article. Clinical Trial.
Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.
Zhao YJ, Jiang N, Song QK, Wu JP, Song YG, Zhang HM, Chen F, Zhou L, Wang XL, Zhou XN, Yang HB, Ren J, Lyerly HK. Zhao YJ, et al. Among authors: jiang n. Asian Pac J Cancer Prev. 2015;16(6):2419-23. doi: 10.7314/apjcp.2015.16.6.2419. Asian Pac J Cancer Prev. 2015. PMID: 25824775 Free article.
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).
Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J, Di L, Song G, Che L, Jia J, Zhou X, Yang H, Lyerly HK. Wang X, et al. Among authors: jiang n. Clin Transl Oncol. 2016 Jan;18(1):82-7. doi: 10.1007/s12094-015-1339-2. Epub 2015 Aug 13. Clin Transl Oncol. 2016. PMID: 26266766 Clinical Trial.
Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.
Ren J, Gwin WR, Zhou X, Wang X, Huang H, Jiang N, Zhou L, Agarwal P, Hobeika A, Crosby E, Hartman ZC, Morse MA, H Eng K, Lyerly HK. Ren J, et al. Among authors: jiang n. Oncoimmunology. 2016 Dec 7;6(4):e1264563. doi: 10.1080/2162402X.2016.1264563. eCollection 2017. Oncoimmunology. 2016. PMID: 28507788 Free PMC article.
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, Huang L, Hobeika A, Yi X, Xia X, Guan Y, Song J, Ren J, Lyerly HK. Jiang N, et al. Clin Cancer Res. 2017 Sep 1;23(17):5066-5073. doi: 10.1158/1078-0432.CCR-17-0492. Epub 2017 Jun 13. Clin Cancer Res. 2017. PMID: 28611200 Clinical Trial.
Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N, Zhou L, Huang H, Zhao J, Morse MA, Hobeika A, Ren J, Lyerly HK. Zhao Y, et al. Among authors: jiang n. Clin Transl Oncol. 2019 Jun;21(6):721-728. doi: 10.1007/s12094-018-1968-3. Epub 2018 Oct 29. Clin Transl Oncol. 2019. PMID: 30374838
5,126 results